[go: up one dir, main page]

WO2005041873A3 - Formulation of exendin-4 - Google Patents

Formulation of exendin-4 Download PDF

Info

Publication number
WO2005041873A3
WO2005041873A3 PCT/US2004/035088 US2004035088W WO2005041873A3 WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3 US 2004035088 W US2004035088 W US 2004035088W WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3
Authority
WO
WIPO (PCT)
Prior art keywords
exendin
articles
methods
formulation
articles made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/035088
Other languages
French (fr)
Other versions
WO2005041873A2 (en
Inventor
Stephen C Rowe
Durga Annavajjula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azopax Therapeutics LLC
Original Assignee
Azopax Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azopax Therapeutics LLC filed Critical Azopax Therapeutics LLC
Publication of WO2005041873A2 publication Critical patent/WO2005041873A2/en
Publication of WO2005041873A3 publication Critical patent/WO2005041873A3/en
Priority to US11/410,269 priority Critical patent/US20070053954A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods and articles for the administration of exendin-4. These methods and articles provide for the controlled and sustained delivery of relatively large quantities of exendin-4 with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
PCT/US2004/035088 2003-10-24 2004-10-25 Formulation of exendin-4 Ceased WO2005041873A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/410,269 US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51424303P 2003-10-24 2003-10-24
US60/514,243 2003-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/410,269 Continuation-In-Part US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Publications (2)

Publication Number Publication Date
WO2005041873A2 WO2005041873A2 (en) 2005-05-12
WO2005041873A3 true WO2005041873A3 (en) 2005-07-21

Family

ID=34549321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035088 Ceased WO2005041873A2 (en) 2003-10-24 2004-10-25 Formulation of exendin-4

Country Status (1)

Country Link
WO (1) WO2005041873A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
CN101193626A (en) 2005-03-11 2008-06-04 益德威士医药股份有限公司 Controlled release formulation of octreotide
HRP20150186T1 (en) 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Exendin for treating diabetes and reducing body weight
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
NZ580803A (en) 2007-04-27 2012-03-30 Endo Pharmaceuticals Solutions Implant device release agents and methods of using same
AU2008306192A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of leptin (22-56 ) as a therapeutic agent
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
JP5622725B2 (en) 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． Sustained delivery of exenatide and other polypeptides
KR20110025974A (en) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. Octreotide Implants Containing Release Agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
WO2005041873A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2005058537A3 (en) Medical devices and methods of making the same
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
AU2003273259A1 (en) Drug cartridge assembly and method of manufacture
WO2002030463A3 (en) Reduced-viscosity concentrated protein formulations
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2005027794A3 (en) Medical devices
WO2009083544A3 (en) Pdgf fusion proteins incorporated into fibrin foams
WO2006042230A8 (en) Medical devices and methods of making the same
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2003011226A3 (en) Products and drug delivery vehicles
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
WO2005009356A3 (en) Method for the preparation of controlled release formulations
AU2003213425A1 (en) Vaporizer, various devices using the same, and vaporizing method
WO2005041873A3 (en) Formulation of exendin-4
PL1638535T3 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
WO2007133944A3 (en) Topical administration of acyclovir
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
WO2005039502A3 (en) Macromer-melt formulations
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2009087658A3 (en) Ketorolac tromethamine containing parenteral formulation
WO2005040195A3 (en) Formulation of exendins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11410269

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11410269

Country of ref document: US